Veracyte Inc (NASDAQ:VCYT)’s share price traded down 6% during mid-day trading on Wednesday . The company traded as low as $22.28 and last traded at $22.93. 752,600 shares changed hands during trading, an increase of 25% from the average session volume of 600,061 shares. The stock had previously closed at $24.39.
A number of equities analysts recently issued reports on the stock. BidaskClub raised shares of Veracyte from a “hold” rating to a “buy” rating in a research report on Monday, January 7th. Zacks Investment Research raised shares of Veracyte from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Friday, February 15th. Finally, BTIG Research boosted their target price on shares of Veracyte to $17.00 and gave the stock a “buy” rating in a research report on Friday, January 4th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $15.83.
The firm has a market cap of $1.01 billion, a PE ratio of -36.98 and a beta of 1.03. The company has a current ratio of 7.42, a quick ratio of 7.16 and a debt-to-equity ratio of 0.30.
Institutional investors have recently made changes to their positions in the business. Group One Trading L.P. acquired a new stake in shares of Veracyte in the 4th quarter valued at $29,000. Tower Research Capital LLC TRC boosted its stake in shares of Veracyte by 562.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 12,640 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 10,732 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Veracyte in the 3rd quarter valued at $127,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Veracyte by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,544 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 8,235 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Veracyte in the 4th quarter valued at $140,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/4300291/veracyte-vcyt-stock-price-down-6.html.
Veracyte Company Profile (NASDAQ:VCYT)
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Featured Article: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.